Conference Reports for NATAP

19th Conference on Retroviruses and Opportunistic Infections Seattle, WA March 5 - 8, 2012 Back

Safety, Tolerability, and PK of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily with Rifampin - Results of a Phase 1 Study among Healthy Volunteers       Reported by Jules Levin CROI 2012 March 5-8 Seattle WA